Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial combines surgery to remove the prostate with either two or three systemic drug therapies for metastatic prostate cancer — given that my cancer has already spread, is my doctor's view that removing the primary tumor could actually help slow things down, or is that still considered experimental at this stage?
2. 2The trial is measuring radiographic progression-free survival, meaning how long before scans show the cancer growing — can my doctor explain what that means for my day-to-day life and whether that endpoint reflects outcomes I actually care about, like living longer or feeling better?
3. 3Since this is a Phase 3 trial comparing triple versus dual drug therapy combined with surgery, what are the known side effects of each combination, and how might adding a third drug or the surgery itself affect my ability to tolerate treatment?
4. 4The trial requires directly observed therapy, which could mean frequent clinic visits or close monitoring — how would that fit into my schedule, and are there travel, work, or family considerations my care team can help me think through before deciding?
5. 5Would my doctor recommend I consider standard-of-care treatment first — such as established hormone therapy combinations without surgery — and how does my specific disease picture compare to what this trial is designed to study?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.